CN106333950A - Medicine for treating mirror image pain due to cancerous invasion - Google Patents
Medicine for treating mirror image pain due to cancerous invasion Download PDFInfo
- Publication number
- CN106333950A CN106333950A CN201510405967.2A CN201510405967A CN106333950A CN 106333950 A CN106333950 A CN 106333950A CN 201510405967 A CN201510405967 A CN 201510405967A CN 106333950 A CN106333950 A CN 106333950A
- Authority
- CN
- China
- Prior art keywords
- component
- compound recipe
- ligustrazine
- salt
- sinomenine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a medicine for treating mirror image pain due to cancerous invasion. The active component of the medicine for treating mirror image pain is a CQ compound; the CQ compound is composed of a component A and a component B; the component A is ligustrazine or ligustrazine salt; the component B is sinomenine or salt of sinomenine; and the mass ratio of the component A to the component B is 0.5-2.5 :1. The invention also provides a second medicine for treating mirror image pain, and the active components are the CQ compound and amantadine hydrochloride. The medicine provides the reference for mechanism research and clinical treatment of mirror image pain due to cancerous invasion, and has great application value for treating mirror image pain.
Description
Technical field
The present invention relates to a kind of medicine treating the mirror-image pain that cancerous invasion causes.
Background technology
Cancer has become as serious harm human health, leads to the first dead big foul disease of modern humans and pertinacious disease.Cancer pain
It is one of modal clinical symptoms of cancer patient, any stage of cancer can be occurred in.Newly it is diagnosed as malignant tumor
Patient in about 1/4 with pain, in therapeutic process, about 1/3 with cancer pain, and progressive stage about 3/4 is with pain.Cancer
Invasion and attack pain (cancer invasion pain, cip) are due to the tumor-infiltrated pain causing, and cancer patient takes place frequently,
It is one of intractable cancer pain.
Also adverse effect is brought, such as body side is damaged out while the symmetry of body offers convenience to human action
When existing pain or pain are quick, the offside antimere (mirror image position) of its damage location Secondary cases pain also and pain is quick,
I.e. mirror-image pain (mirror image pain, mip).This phenomenon is found in American Civil War period earliest, and limbs are injured
Soldier also occur in that pain perception in the limbs of injured offside.Clinically, some serious chronic pains are (as congenital
Property facial joint myalgia, atypical facial pain, chronic migraine, tension-type headache etc.), complex region pain syndrome
Levy, amputation and apoplexy sequela all may occur in which insecondary mip, bring great misery to minimal invasive treatment.
Because mip generation, development be not still fully aware of so far with the mechanism maintaining, therapeutic effect is also undesirable, typically
The medicine for the treatment of pain is uncertain to the therapeutic effect of mip.
Content of the invention
It is an object of the invention to provide a kind of medicine treating the mirror-image pain that cancerous invasion causes.
The invention provides a kind of medicine treating mirror-image pain, its active component is cq compound recipe.
Present invention also offers second treats the medicine of mirror-image pain, its active component is described cq compound recipe and hydrochloric acid gold
Just alkanamine.Amantadine hydrochloride uses as the synergist of cq compound recipe, using in the acceptable dosage range of human body
Amount.The mass ratio of described cq compound recipe and described amantadine hydrochloride is can be 3:3-5, concretely 3:4.
Present invention also offers a kind of medicine treating the mirror-image pain that cancerous invasion causes, its active component is that described cq is multiple
Side.The described cancerous invasion cancerous invasion that concretely s180 tumor strain cell causes.
Present invention also offers second treats the medicine of the mirror-image pain that cancerous invasion causes, its active component is described cq
Compound recipe and amantadine hydrochloride.The described cancerous invasion cancerous invasion that concretely s180 tumor strain cell causes.Hydrochloric acid Buddha's warrior attendant
Alkanamine uses as the synergist of cq compound recipe, using the amount in the acceptable dosage range of human body.Described cq is multiple
The mass ratio of square and described amantadine hydrochloride is can be 3:3-5, concretely 3:4.
The present invention also protects application in the medicine of preparation treatment mirror-image pain for the described cq compound recipe.
The present invention also protects the application in the medicine of preparation treatment mirror-image pain of described cq compound recipe and amantadine hydrochloride.
Amantadine hydrochloride uses as the synergist of cq compound recipe, using the amount in the acceptable dosage range of human body.
The mass ratio of described cq compound recipe and described amantadine hydrochloride is can be 3:3-5, concretely 3:4.
The present invention also protects application in the medicine of the mirror-image pain that preparation treatment cancerous invasion causes for the described cq compound recipe.Institute
State the cancerous invasion cancerous invasion that concretely s180 tumor strain cell causes.
The present invention also protects described cq compound recipe and amantadine hydrochloride to treat the medicine of the mirror-image pain that cancerous invasion causes in preparation
Application in thing.The described cancerous invasion cancerous invasion that concretely s180 tumor strain cell causes.Amantadine hydrochloride conduct
The synergist of cq compound recipe uses, using the amount in the acceptable dosage range of human body.Described cq compound recipe and described
The mass ratio of amantadine hydrochloride is can be 3:3-5, concretely 3:4.
Described cq compound recipe is made up of component first and component second；Described component first is the salt of ligustrazine or ligustrazine；Described
Component second is the salt of sinomenine or sinomenine；The mass ratio of described component first and described component second is 0.5-2.5:1.Institute
The salt stating ligustrazine is ligustrazine hydrochloride or ligustrazine phosphate；The salt of described sinomenine is sinomenine hydrochloride or phosphoric acid Sinomenium acutum
Alkali.The mass ratio of described component first and described component second is 0.8:1.
Described in any of the above, " mirror-image pain that treatment cancerous invasion causes " is presented as following (a) and/or (b) and/or (c)
And/or (d) and/or (e): (a) promotes mechanical pain threshold to increase；B () promotes rantes content in myeloid tissue
Reduce；C () promotes mcp-3 content in myeloid tissue to reduce；D () promotes il-6 content in serum to reduce；(e)
Mcp-1 content in serum is promoted to reduce.
The present invention is the Mechanism Study of cancerous invasion mirror-image pain and clinical treatment provides reference, and the treatment for mirror-image pain has
Great using value.
Brief description
Fig. 1 be each group mice cancerous invasion side (figure a) and image side (figure b) metapedes mechanical threshold of pain value changes ( N=13)；*P < 0.05,**P < 0.01, compared with native group；#P < 0.05,##P < 0.01, with sham group phase
Than.
The impact (figure a is cancerous invasion side, and figure b is image side) that Fig. 2 acts on to cq compound pain for amantadine hydrochloride；*p<0.05,**P < 0.01, compared with cq group.
Specific embodiment
Below example facilitates a better understanding of the present invention, but does not limit the present invention.Experiment in following embodiments
Method, if no special instructions, is conventional method.Test material used in following embodiments, if no special instructions,
It is and be commercially available from routine biochemistry reagent shop.Quantitative test in following examples, is respectively provided with three repetitions,
Results averaged.
Spf level balb/c male mice, body weight is 18-20g, is purchased from National Institute for Food and Drugs Control, licence
Number: scxk (capital) 2014-0013.
S180 tumor strain cell (murine sarcoma cells strain): list of references: lee hj, lee jh, lee eo, et
al.substance p and beta-endorphin mediate electro-acupuncture induced
Analgesia in mouse cancer pain model [j] .acupunctelectrother res, 2009,
34(1-2):27-40.
Muose custom 8-plex kit: Beijing Quanto Biotechnology Co., Ltd.；Article No.:
t2c081217.Mouse group 116-plex kit: Beijing Quanto Biotechnology Co., Ltd.,
Article No.: c261116.
The detection method of mechanical pain threshold (paw withdrawal threshold value): successively with standardized different stimulated dynamics (0.008g,
0.02g, 0.04g, 0.07g, 0.16g, 0.4g, 0.6g, 1g or 2g；From the beginning of 0.008g, with once per second
Frequency) von frey cellosilk, vertical stimulate outside skin surface in mouse hind leg foot pawl bottom, observe little
The paw withdrawal reaction of Mus, long run test 5 times, the minimum cellosilk value of 3 times or more than 3 times paw withdrawal reactions in record,
As mechanical pain threshold.
Animal Behavior Science data adds and subtracts standard error with meanRepresent, united using spss 21.0 software
Meter analysis.For repeated measure mechanical threshold group difference adopt general linear model Repeated Measurement Data variance
Analysis method detects group difference, the group difference specifically sometime put using the analysis of multifactor analysis of variance method.
Cytokines measurement data adds and subtracts standard deviation with meanRepresent, between two groups, data analysiss adopt independent sample t
Inspection, statistically significant for difference with p < 0.05.
It is related in embodiment 1 and embodiment 2 operate continuously, therefore continuous meter test natural law.
The structural formula of ligustrazine hydrochloride is as follows:
The structural formula of sinomenine hydrochloride is as follows:
Ligustrazine can be extracted from Rhizoma Chuanxiong and obtain it is also possible to be obtained by the method for chemosynthesis.Common extraction side
Method is as follows: Rhizoma Chuanxiong ethanol ultrasonic extraction, and extracting solution concentrate drying obtains final product.Ligustrazine also can be by the salt generation of ligustrazine
Replace, for example ligustrazine hydrochloride, ligustrazine phosphate etc..
Sinomenine can extract from Caulis Sinomenii and obtain.Common extracting method is as follows: 1, Sinomenium acutum alcohol extraction, and acid is molten,
Extraction, water recrystallization, obtain final product；2nd, Sinomenium acutum alkalization, benzene carries, crystallization, decolouring, and water recrystallization obtains final product.Due to
The development of chemical synthesising technology, sinomenine can also be obtained by the method for synthesis.Sinomenine also can be by the salt of sinomenine
Replace, such as sinomenine hydrochloride, phosphoric acid sinomenine etc..
Amantadine hydrochloride: Northeast Pharmaceutical Group Shenyang First Pharmaceutical Co., Ltd., lot number: 5140102.
Embodiment 1, mice cancerous invasion mirror-image pain (cancer invasion induced mirror image pain,
Ciimip) the foundation of model
For three days on end spf level balb/c male mice is carried out with pre-stimulation (once a day, every time with quantitative von before test
Frey cellosilk stimulates the metapedes of mice bilateral).Test the 1st day mice by equal for bilateral metapedes machinery pain threshold >=0.4g
It is randomly divided into normal group (native), operation matched group (sham), operation group (surgery), surgery group every
Mice injects 0.2ml s180 tumor strain Cell sap in right lower limb greater trochanter of femur (being equivalent to above sciatic nerve branch part)
(viable cell concentrations are 1 × 107Individual/ml), sham group injects the inactivation s180 of same volume same concentrations in same area
Tumor strain Cell sap (ablation method: boil 15min in boiling water, then Trypan Blue determines no living cells), native
Group does not make any operation.
Test the 4th day, surgery group mice activity reduces, hair color is partially dark, and the mental status is not good.Test the 4th
My god, substantially, art parapodum toe is unable to normal extension, in protection to the major part neoplasm lines inoculation position enlargement of surgery group
Property is turned up position, and the tumor size of its leg and toes deformation extent are gradually increased in time.Test the 11st day,
Surgery group mice leg tumor is found in sciatic nerve bifurcation, tumour growth is progressively oppressed or invaded after dissection
Attack sciatic nerve, the weight isolating tumor tissues in mice leg tissue is 1.493 ± 0.725g.Test the 11st day,
Sham group mice leg has no tumor tissues.
Test the machinery pain continuously evaluating native group, sham group and surgery group mice cancerous invasion side the 2-7 days
Threshold value, finds that between three groups of cancerous invasion side machinery pain threshold groups, there were significant differences (p < 0.01), sees Fig. 1 a.surgery
Group mice cancerous invasion side machinery pain threshold begins to decline in test on the 2nd day, and test the is all stably maintained at for 4-7 days
(0.031 ± 0.006) g- (0.057 ± 0.029) g is hence it is evident that be less than sham group and native group (p < 0.05 or p < 0.01).
The cancerous invasion side machinery pain threshold of sham group mice also reduces in test on the 2nd day, but subsequently gradually gos up, and tests the 5th
Native group level is reached after it.Continuously evaluate within the 2-7 days native group, sham group and surgery in test
The mechanical pain threshold of group mice image side, finds that between three groups of mice image side machinery pain threshold groups, also there were significant differences
(p < 0.01), is shown in Fig. 1 b.Surgery group mice image side machinery pain threshold also declines in test on the 2nd day, test
The is all stably maintained at (0.044 ± 0.012) g- (0.101 ± 0.038) g for 4-7 days hence it is evident that being less than sham group and native
Group (p < 0.05 or p < 0.01).Surgery group mice left fore and abdominal part have no obvious pain in test in the 16th day
Pain shows, and shows that the quick phenomenon of pain occurs over just the mirror image position of cancerous invasion side.
Test the 5-7 days, the mechanical pain threshold of cancerous invasion side and image side all≤the surgery group mice of 0.07g, that is,
For model mice.
Embodiment 2, the action effect to cancerous invasion mirror-image pain for the cq compound recipe
First, prepare cq compound recipe
Cq compound recipe is made up of ligustrazine hydrochloride and sinomenine hydrochloride, and the mass ratio of ligustrazine hydrochloride and sinomenine hydrochloride is
0.8:1.Take cq compound recipe, use ultrapure water dissolution, obtain the storing liquid of 40mg/ml, then use normal saline dilution, obtain
To cq compound recipe solution.
2nd, packet administration
Model group (model, n=12): the model mice that object obtains for embodiment 1, test the 8th day, the 9th day
Each normal saline of lumbar injection with the 10th day, bolus doses are 0.4ml normal saline/20g mice；
The model mice that cq compound recipe high dose group (h-cq, 200mg/kg, n=12): object obtains for embodiment 1,
Test the 8th day, the 9th day and the 10th day each cq compound recipe solution of lumbar injection, bolus doses are 0.4ml cq
Compound recipe solution/20g mice, in 0.4ml cq compound recipe solution, the concentration of cq compound recipe is 10mg/ml；
The model mice that cq compound recipe middle dose group (m-cq, 150mg/kg, n=11): object obtains for embodiment 1,
Test the 8th day, the 9th day and the 10th day each cq compound recipe solution of lumbar injection, bolus doses are 0.4ml cq
Compound recipe solution/20g mice, in 0.4ml cq compound recipe solution, the concentration of cq compound recipe is 7.5mg/ml；
The model mice that cq compound recipe low dose group (l-cq, 100mg/kg, n=11): object obtains for embodiment 1,
Test the 8th day, the 9th day and the 10th day each cq compound recipe solution of lumbar injection, bolus doses are 0.4ml cq
Compound recipe solution/20g mice, in 0.4ml cq compound recipe solution, the concentration of cq compound recipe is 5mg/ml；
Sham group (sham, n=11): object be embodiment 1 in sham group mice, test the 8th day, the 9th
It and the 10th day each normal saline of lumbar injection, bolus doses are 0.4ml normal saline/20g mice；
Native group (native, n=13): object is the native group mice in embodiment 1, test the 8th day,
9th day and the 10th day each normal saline of lumbar injection, bolus doses are that 0.4ml normal saline/20g is little
Mus.
3rd, the mechanical pain threshold of mice after cq compound recipe is administered
Test the 10th day, the mice cancerous invasion side machinery pain threshold evaluating result before administration and in 240min after administration is shown in
Tables 1 and 2.
Table 1 is tested the 10th day, machinery pain threshold in cancerous invasion side before and after the administration of each group mice
| Before administration | 30min after administration | 60min after administration | 90min after administration | 120min after administration | 180min after administration | 240min after administration | |
| native | 0.37±0.07 | 0.38±0.07 | 0.34±0.05 | 0.37±0.05 | 0.35±0.05 | 0.40±0.06 | 0.37±0.05 |
| sham | 0.24±0.05 | 0.22±0.05 | 0.22±0.05 | 0.26±0.05 | 0.27±0.04 | 0.25±0.04 | 0.26±0.04 |
| model | 0.02±0.00**## | 0.03±0.01**## | 0.03±0.01**## | 0.03±0.01**## | 0.02±0.01**## | 0.02±0.01**## | 0.02±0.01**## |
| l-cq | 0.01±0.00 | 0.22±0.18 | 0.22±0.18 | 0.32±0.18 | 0.32±0.19 | 0.15±0.06 | 0.07±0.03 |
| m-cq | 0.02±0.01 | 0.73±0.27△ | 0.72±0.27△ | 0.76±0.27△ | 0.59±0.22△ | 0.33±0.10△ | 0.28±0.13 |
| h-cq | 0.03±0.01 | 1.33±0.25△△ | 1.31±0.22△△ | 1.22±0.21△△ | 0.86±0.17△△ | 0.47±0.15△ | 0.30±0.16 |
**P < 0.01, compared with native group；##P < 0.01, compared with sham group；△P < 0.05,△△P < 0.01, with model
Group is compared.
Table 2 is tested the 10th day, each group mice administration front and rear mirror image side machinery pain threshold
| Before administration | 30min after administration | 60min after administration | 90min after administration | 120min after administration | 180min after administration | 240mi after administration | |
| native | 0.47±0.10 | 0.47±0.19 | 0.45±0.10 | 0.47±0.09 | 0.42±0.09 | 0.42±0.09 | 0.48±0.14 |
| sham | 0.26±0.05 | 0.22±0.06 | 0.28±0.05 | 0.26±0.05 | 0.26±0.05 | 0.30±0.06 | 0.28±0.05 |
| model | 0.03±0.01**## | 0.03±0.02**## | 0.03±0.01**## | 0.03±0.01**## | 0.03±0.01**## | 0.03±0.01**## | 0.03±0.01**## |
| l-cq | 0.02±0.00 | 0.11±0.05 | 0.41±0.24 | 0.30±0.18 | 0.15±0.07 | 0.16±0.06 | 0.05±0.01 |
| m-cq | 0.04±0.01 | 0.09±0.04 | 0.68±0.24△ | 0.84±0.26△ | 0.58±0.20△ | 0.22±0.06△ | 0.21±0.06△ |
| h-cq | 0.06±0.03 | 0.98±0.42△△ | 1.23±0.21△△ | 1.27±0.19△△ | 0.85±0.15△△ | 0.37±0.09△△ | 0.32±0.11△ |
**P < 0.01, compared with native group；##P < 0.01, compared with sham group；△P < 0.05,△△P < 0.01, with model
Group is compared.
Result shows, after application cq compound recipe, the idiopathic cip of model mice substantially mitigates, and insecondary mip is also
It is relieved, all 30min starts to play obvious analgesic activity, typically in 30min or 60min upon administration
When reach drug effect peak, 240min still has preferable analgesic effect, and between dosage group be in obvious dose-effect dependence.
4th, the content of rantes and mcp-3 in mouse spinal cord tissue after cq compound recipe is administered
Rantes, mcp-3 belong to chemotactic factor in spinal cord.
Test the 11st day and put to death mice, take l3-l5 section myeloid tissue, through homogenate, Deproteinization, go microgranule to obtain spinal cord
The treatment fluid of homogenate, using rantes in aimplex streaming high flux multiple-factor detection technique detection mouse spinal cord tissue
Content with mcp-3.
The results are shown in Table 3.Compared with sham group, rantes, mcp-3 content in model group all significantly raise (p < 0.01,
P < 0.05), l-cq and h-cq all can significantly reduce the content of rantes, mcp-3 in model mice myeloid tissue
(p<0.05).
Rantes, mcp-3 content in myeloid tissue after the administration of table 3cq compound recipe
#P < 0.05,##P < 0.01, compared with sham group；△P < 0.05, compared with model group.
5th, the content of inflammatory factor il-6 and chemotactic factor mcp-1 in mice serum after cq compound recipe is administered
Before testing the 11st day sacrifice, eye socket takes blood, collects serum, using aimplex streaming high flux multiple-factor
Detection technique detects the content of inflammatory factor il-6 and chemotactic factor mcp-1 in mice serum.
The results are shown in Table 4.Compared with native group, il-6, mcp-1 content in model group model mice serum is equal
Notable rising (p < 0.05), cq compound recipe can significantly reduce the content (p < 0.01) of il-6, mcp-1 in model mice serum.
The content of inflammatory factor il-6 and chemotactic factor mcp-1 in mice serum after the administration of table 4cq compound recipe
*P < 0.05, compared with native group；△△P < 0.01, compared with model group.
Embodiment 3, amantadine hydrochloride strengthen the analgesic activity for mip for the cq compound recipe
First, prepare model mice
For three days on end spf level balb/c male mice is carried out with pre-stimulation (once a day, every time with quantitative von before test
Frey cellosilk stimulates the metapedes of mice bilateral).Test the 1st day take bilateral metapedes machinery pain threshold all >=0.4g little
Mus, every mice injects 0.2ml s180 tumor in right lower limb greater trochanter of femur (being equivalent to above sciatic nerve branch part)
(viable cell concentrations are 1 × 10 to strain Cell sap7Individual/ml).Test the 5-7 days, the mechanical threshold of pain of cancerous invasion side and image side
It is worth the surgery group mice of all≤0.07g, as model mice.
2nd, prepare cq compound recipe
Cq compound recipe is made up of ligustrazine hydrochloride and sinomenine hydrochloride, and the mass ratio of ligustrazine hydrochloride and sinomenine hydrochloride is
0.8:1.Take cq compound recipe, use ultrapure water dissolution, obtain the storing liquid of 40mg/ml, then use normal saline dilution, obtain
To cq compound recipe solution.
3rd, packet administration
Amantadine hydrochloride solution: take amantadine hydrochloride (ama), use normal saline ultrasonic dissolution, obtain 10mg/ml
Amantadine hydrochloride solution.
Ama+cq group (n=12): the model mice that object obtains for step one, test the 8th day, lumbar injection is once
(150mg/kg, injection dosage is 0.4ml cq compound recipe solution/20g mice to cq compound recipe solution, and 0.4ml cq compound recipe is molten
In liquid, the concentration of cq compound recipe is 7.5mg/ml), before lumbar injection cq compound recipe solution 30min, gavage gives 10mg/ml
Amantadine hydrochloride solution (200mg/kg, dosage be 0.4ml/20g mice).
Cq group (n=11): the model mice that object obtains for step one, test cq compound recipe of the 8th day lumbar injection
(injection dosage is 0.4mlcq compound recipe solution/20g mice to solution, the concentration of cq compound recipe in 0.4mlcq compound recipe solution
For 7.5mg/ml)；
In -30min (before giving ama), 0min (before lumbar injection cq compound recipe) and 30 after giving cq compound recipe, 60,
90th, 120,180,240min equi-time point is tested and assessed the mechanical pain threshold of bilateral metapedes.
Before ciimip model mice abdominal cavity gives cq compound recipe 30min, gavage gives ama and can strengthen cq compound recipe pair
Model mice cancerous invasion side and the rising effect of image side machinery pain threshold.6 time in 30-240min upon administration
Point all can significantly increase the analgesic activity (p < 0.01 or p < 0.05) for cip for the cq compound recipe, sees Fig. 2 a.In administration
Afterwards 5 times of 30-180min all can significantly increase cq compound recipe for mip analgesic activity (p < 0.01 or
P < 0.05), see Fig. 2 b.
Claims (10)
1. a kind of medicine treating mirror-image pain, its active component is cq compound recipe；Described cq compound recipe is by component first and component
Second forms；Described component first is the salt of ligustrazine or ligustrazine；Described component second is the salt of sinomenine or sinomenine；Institute
Stating component first and the mass ratio of described component second is 0.5-2.5:1.
2. a kind of medicine treating mirror-image pain, its active component is cq compound recipe and amantadine hydrochloride；Described cq compound recipe
It is made up of component first and component second；Described component first is the salt of ligustrazine or ligustrazine；Described component second be sinomenine or
The salt of sinomenine；The mass ratio of described component first and described component second is 0.5-2.5:1.
3. a kind of medicine treating the mirror-image pain that cancerous invasion causes, its active component is cq compound recipe；Described cq compound recipe by
Component first and component second composition；Described component first is the salt of ligustrazine or ligustrazine；Described component second is sinomenine or green grass or young crops
The salt of rattan alkali；The mass ratio of described component first and described component second is 0.5-2.5:1.
4. a kind of medicine treating the mirror-image pain that cancerous invasion causes, its active component is cq compound recipe and amantadine hydrochloride；
Described cq compound recipe is made up of component first and component second；Described component first is the salt of ligustrazine or ligustrazine；Described component second
Salt for sinomenine or sinomenine；The mass ratio of described component first and described component second is 0.5-2.5:1.
Application in the medicine of preparation treatment mirror-image pain for the 5.cq compound recipe；Described cq compound recipe is by component first and component second group
Become；Described component first is the salt of ligustrazine or ligustrazine；Described component second is the salt of sinomenine or sinomenine；Described group
The mass ratio of point first and described component second is 0.5-2.5:1.
The application in the medicine of preparation treatment mirror-image pain of 6.cq compound recipe and amantadine hydrochloride；Described cq compound recipe is by group
Divide first and component second composition；Described component first is the salt of ligustrazine or ligustrazine；Described component second is sinomenine or Sinomenium acutum
The salt of alkali；The mass ratio of described component first and described component second is 0.5-2.5:1.
Application in the medicine of the mirror-image pain that preparation treatment cancerous invasion causes for the 7.cq compound recipe；Described cq compound recipe is by component
First and component second composition；Described component first is the salt of ligustrazine or ligustrazine；Described component second is sinomenine or sinomenine
Salt；The mass ratio of described component first and described component second is 0.5-2.5:1.
The application in the medicine of the mirror-image pain that preparation treatment cancerous invasion causes of 8.cq compound recipe and amantadine hydrochloride；Institute
State cq compound recipe to be made up of component first and component second；Described component first is the salt of ligustrazine or ligustrazine；Described component second is
Sinomenine or the salt of sinomenine；The mass ratio of described component first and described component second is 0.5-2.5:1.
9. such as described medicine arbitrary in Claims 1-4 or as described application arbitrary in claim 5 to 8,
It is characterized in that: the salt of described ligustrazine is ligustrazine hydrochloride or ligustrazine phosphate；The salt of described sinomenine is that hydrochloric acid is blue or green
Rattan alkali or phosphoric acid sinomenine；The mass ratio of described component first and described component second is 0.8:1.
10. the medicine as described in claim 2 or 4 or the application as described in claim 6 or 8 it is characterised in that:
The mass ratio of described cq compound recipe and described amantadine hydrochloride is 3:3-5.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510405967.2A CN106333950B (en) | 2015-07-10 | 2015-07-10 | A kind of drug for treating mirror-image pain caused by cancerous invasion |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510405967.2A CN106333950B (en) | 2015-07-10 | 2015-07-10 | A kind of drug for treating mirror-image pain caused by cancerous invasion |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106333950A true CN106333950A (en) | 2017-01-18 |
| CN106333950B CN106333950B (en) | 2019-04-02 |
Family
ID=57826580
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510405967.2A Active CN106333950B (en) | 2015-07-10 | 2015-07-10 | A kind of drug for treating mirror-image pain caused by cancerous invasion |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106333950B (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1634057A (en) * | 2004-12-13 | 2005-07-06 | 北京正大绿洲医药科技有限公司 | Dripping pills for reducing swelling and easing pain and its preparing method |
| CN101411707A (en) * | 2008-10-10 | 2009-04-22 | 西南大学 | Pharmaceutical composition for treating rheumatoid arthritis |
| CN103083401A (en) * | 2012-12-31 | 2013-05-08 | 中国中医科学院医学实验中心 | Compound pharmaceutical composition comprising szechwan lovage rhizome extract and caulis sinomenii extract |
-
2015
- 2015-07-10 CN CN201510405967.2A patent/CN106333950B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1634057A (en) * | 2004-12-13 | 2005-07-06 | 北京正大绿洲医药科技有限公司 | Dripping pills for reducing swelling and easing pain and its preparing method |
| CN101411707A (en) * | 2008-10-10 | 2009-04-22 | 西南大学 | Pharmaceutical composition for treating rheumatoid arthritis |
| CN103083401A (en) * | 2012-12-31 | 2013-05-08 | 中国中医科学院医学实验中心 | Compound pharmaceutical composition comprising szechwan lovage rhizome extract and caulis sinomenii extract |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106333950B (en) | 2019-04-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11737810B2 (en) | Immunotherapeutic methods using electroporation | |
| US9603866B2 (en) | Anti-fatigue composition, formulation and use thereof | |
| CN107412726A (en) | With the method for GNRH antagonists Ac-D-2Nal-D-4Cpa-D-3Pal-Ser-4Aph(Hor)-D-4Aph(Cbm)-Leu-Lys(iPr)-Pro-D-Ala-NH2 treatment prostate cancer | |
| Severcan et al. | The effects of acupuncture on the levels of blood pressure and nitric oxide in hypertensive patients | |
| Batista et al. | Salt-dependent hypertension and inflammation: Targeting the gut–brain axis and the immune system with Brazilian green propolis | |
| Kang et al. | Phase I study of chlorogenic acid injection for recurrent high-grade glioma with long-term follow-up | |
| US10561678B2 (en) | Composition for treating neuropathy, process and method of treatment thereof | |
| JP6757897B2 (en) | Test method | |
| CN106333950A (en) | Medicine for treating mirror image pain due to cancerous invasion | |
| Giorgi et al. | Pharmacokinetics of tramadol after epidural administration in horses | |
| CN114159460A (en) | Application of composition comprising ginsenoside Rg1 and fucoidin in preparation of drug for reducing expression of high-mobility group protein B1 | |
| Gao et al. | Radix astragali and orthostatic response: a double-masked crossover study | |
| CN109925342A (en) | New application of the Tanreqing in preparation glioma treatment drug | |
| CN1329056C (en) | Medicine composition | |
| CN103690484B (en) | Medicine composition containing alprostadil and preparation method of medicine composition | |
| CN105287805A (en) | Traditional Chinese medicine combination extract and application thereof in preparation of medicines for treating cervical carcinoma | |
| Choate et al. | 033 HD Real-Time Video Assessment of Catastrophic Venous Bleeding and Control from Reservoir Manipulation | |
| CN101172113A (en) | Application of Tween 80 injection in substance base and thermotherapy for treating tumour | |
| Mansour et al. | A Nano Breakthrough Fast Natural Cure for Prostate Cancer | |
| Zhi et al. | Peridural injection of Mailuoning compound liquor for treatment of prolapse of lumbar intervertebral disc in 100 cases | |
| Cai et al. | Ophiopogon japonicas (Linn. f.) Ker-Gawl. extract ameliorates chronic heart failure in rats | |
| Mansour et al. | IMUTECH a nano natural immune therapy for treating cancer | |
| CN103463170B (en) | Hyperosteogeny treatment traditional Chinese medicine effective fraction composition and preparation method thereof | |
| CN115671109A (en) | Application of sitagliptin phosphate | |
| Barlier et al. | Strong additive effect of everolimus and octreotide or pasireotide on meningioma cells in vitro: a new therapeutic strategy for these tumors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |